Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents

[1]  T. Shen,et al.  Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. , 2014, Leukemia research.

[2]  R. Bataille,et al.  Multiple myeloma international staging system: "staging" or simply "aging" system? , 2013, Clinical lymphoma, myeloma & leukemia.

[3]  R. Wäsch,et al.  Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. , 2013, Clinical lymphoma, myeloma & leukemia.

[4]  H. Goldschmidt,et al.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[5]  M. Taniwaki,et al.  Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma , 2013, Expert review of anticancer therapy.

[6]  J. H. Lee,et al.  The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. , 2013, Leukemia research.

[7]  N. Nassif,et al.  Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance , 2013, Blood Cancer Journal.

[8]  G. Morgan,et al.  Improved risk stratification in myeloma using a microRNA‐based classifier , 2013, British journal of haematology.

[9]  M. Dimopoulos,et al.  Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents , 2013, Hematological oncology.

[10]  Michael L. Wang,et al.  Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study , 2013, Leukemia.

[11]  M. Kizaki,et al.  Current approaches for the treatment of multiple myeloma , 2013, International Journal of Hematology.

[12]  P. L. Bergsagel,et al.  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. , 2013, Blood.

[13]  G. Treglia,et al.  Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma? , 2012, International Journal of Hematology.

[14]  S. Jagannath,et al.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Taniwaki,et al.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma , 2012, International Journal of Hematology.

[16]  P. Kapoor,et al.  Update on risk stratification and treatment of newly diagnosed multiple myeloma , 2011, International journal of hematology.

[17]  S. Mandrekar,et al.  Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis , 2011, Leukemia.

[18]  R. Wäsch,et al.  Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score , 2011, Blood cancer journal.

[19]  P. Fayers,et al.  Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. , 2011, Blood.

[20]  G. Morgan,et al.  Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. , 2011, Blood.

[21]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[22]  P. Fayers,et al.  Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. , 2010, Blood.

[23]  P. Sonneveld,et al.  Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Barlogie,et al.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. , 2010, Blood.

[25]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Mandrekar,et al.  Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. , 2009 .

[27]  B. Barlogie,et al.  The molecular characterization and clinical management of multiple myeloma in the post-genome era , 2009, Leukemia.

[28]  R. Greil,et al.  Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. , 2009, Blood.

[29]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[30]  B. Pégourié,et al.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.

[31]  Vincenzo Callea,et al.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.

[32]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[33]  J. Miguel,et al.  Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma , 2004, British journal of haematology.

[34]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Bergsagel,et al.  Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). , 1962, Cancer chemotherapy reports.

[36]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[37]  P. Loehrer,et al.  International Staging System for Multiple Myeloma , 2006 .

[38]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[39]  Mike Clarke,et al.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  W. Vaughn,et al.  Melphalan therapy for plasma cell myeloma. , 1968, Blood.